Chicago—Advances in the treatment of myasthenia gravis have come a long way and mortality from the disease now occurs in less than 5% of affected individuals. But current therapies are nonspecific and can cause a variety of adverse effects and health risks.
Researchers are hopeful that improved therapies could battle the disease more effectively and provide patients with a better quality of life. Scientists pursuing research that might lead to new treatment options for patients with this rare chronic autoimmune neuromuscular disorder met here recently at the International Conference on Myasthenia Gravis and Related Disorders to discuss promising new findings.
Hampton T. Novel Therapies Target Myasthenia Gravis. JAMA. 2007;298(2):163–164. doi:10.1001/jama.298.2.163
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: